Literature DB >> 6498626

Low extracellular Ca2+ and enzyme release in the perfused rabbit heart.

P A Fortier, G K Bedford, M A Chiong.   

Abstract

Previous studies have shown that the well-oxygenated perfused rabbit heart releases creatine kinase when treated with the calcium antagonist drug verapamil (VER) in a dose-related manner. It is possible that this effect is related to Ca2+ ion deprivation of the sarcolemma. This possibility was explored by perfusing hearts with low Ca2+ (0.5, 0.23, 0.15, and 0 mM) versus a control group (1.27 mM Ca2+) for 60 min. Low Ca2+ perfusion was associated with reduction in the heart rate--left ventricular systolic pressure product and O2 consumption, tendency for the coronary sinus flow to increase, electromechanical dissociation, prolongation of atrioventricular conduction and QT interval, and decrease in myocardial glycogen. Lower total adenosine nucleotides were found only in the 0 mM Ca2+ group. As the Ca2+ concentration was reduced, the hearts lost increasing amounts of creatine kinase, aspartate aminotransferase, and lactate dehydrogenase. These results confirm the importance of Ca2+ ions in contractile and electrical cardiac functions and show that decreased availability of this cation leads to increasing enzyme leakage resembling that seen in VER-treated hearts.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6498626     DOI: 10.1139/y84-194

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  2 in total

1.  Release of secondary free radicals during post-ischaemic reperfusion is not influenced by extracellular calcium levels in isolated rat hearts.

Authors:  C Perrin-Sarrado; O Bouchot; C Vergely; L Rochette
Journal:  Mol Cell Biochem       Date:  2006-11-02       Impact factor: 3.396

Review 2.  Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.

Authors:  Thomas Meyer; Karl-Heinz Boven; Elke Günther; Michael Fejtl
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.